肝硬化,生化检验项目,诊断价值," /> 肝硬化,生化检验项目,诊断价值,"/> Liver cirrhosis;Biochemical test items;Diagnostic value,"/>  生化检验项目在肝硬化疾病患者中的变化及意义
中国当代医药
中国当代医药杂志欢迎您 今天是   2025年4月3日星期四
设为首页  加入收藏  联系我们         
 
      首 页    |    本刊简介     |    期刊荣誉     |    编采团队     |    会务培训     |    理事单位     |    下载专区     |    在线留言     |    联系我们     |     返回中国当代医药网
中国当代医药  2020, Vol. 27 Issue (33): 164-166    
  肿瘤医学 本期目录 | 过刊浏览 | 高级检索 |
 生化检验项目在肝硬化疾病患者中的变化及意义
 纪金玲 程晓彤 王 茜 朱天星 杨娇娜
 辽宁省辽阳市传染病医院检验科,辽宁辽阳 111000
 Changes and significance of biochemical test items in patients with liver cirrhosis
 JI Jin-ling CHENG Xiao-tong WANG Qian ZHU Tian-xing YANG Jiao-na
 Department of Laboratory,Liaoyang Infectious Disease Hospital,Liaoning Province,Liaoyang 111000,China
全文: PDF (0 KB)   HTML (30 KB) 
输出: BibTeX | EndNote (RIS)       背景资料
文章导读  
摘要  目的 分析生化检验项目在肝硬化疾病患者中的变化及意义。方法 随机选取2017年6月~2019年6月于辽阳市传染病医院进行治疗的160例肝硬化疾病患者作为观察组,其中早期患者53例(33.13%),中期患者53例(33.13%),晚期患者54例(33.75%)。再选取同一时间段到院体检的160例健康者作为对照组。采集两组的静脉血液样本并作为生化检验样本,随后针对主要的生化检验项目采用全自动生化分析仪实施检验,比较两组的生化检验项目。结果 观察组的N-乙酰-β-d 氨基葡萄糖苷酶(NAG)、α-岩藻糖苷酶(AFU)、前白蛋白(PAB)、亮氨酸氨基肽酶(LAP)、天冬氨酸氨基转移同工酶(ASTm)、谷氨酸脱氢酶(GLDH)、腺苷脱氨酶(ADA)、甲胎蛋白(AFP)水平均高于对照组,差异有统计学意义(P<0.05);晚期患者的NAG、AFU、PAB、LAP、ASTm、GLDH、ADA、AFP水平均高于早期患者和中期患者,中期患者的NAG、AFU、PAB、LAP、ASTm、GLDH、ADA、AFP水平均高于早期患者,差异有统计学意义(P<0.05)。结论 针对临床中接诊的肝硬化疾病患者实施生化检验项目进行诊断,可为后期临床治疗提供有效的参考价值,促使临床准确率显著提升。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
纪金玲 程晓彤 王 茜 朱天星 杨娇娜
关键词  font-size: 16pxtext-align: justify肝硬化')" href="#">">肝硬化生化检验项目诊断价值    
Abstract: Objective To analyze the changes and significance of biochemical test items in patients with liver cirrhosis.Methods A total of 160 patients with liver cirrhosis who were treated in Liaoyang Infectious Disease Hospital from June 2017 to June 2019 were randomly selected as the observation group.Among them,53 patients were in the early stage (33.13%),53 patients were in the middle stage (33.13%),and 54 patients (33.75%) were in the late stage.Then 160 healthy people who came to the hospital for physical examination during the same time period were selected as the control group.The venous blood samples of the two groups were collected and used as biochemical test samples,and then the main biochemical test items were tested with an automatic biochemical analyzer to compare the biochemical test items of the two groups.Results The levels of N-acetyl-β-d glucosaminidase (NAG),α-fucosidase (AFU),prealbumin (PAB),leucine aminopeptidase (LAP),aspartate amino transfer isoenzyme (ASTm),glutamate dehydrogenase(GLDH),adenosine deaminase (ADA) and α-fetoprotein (AFP) in the observation group were higher than those in the control group,and the differences were statistically significant (P<0.05).The levels of NAG,AFU,PAB,LAP,ASTm,GLDH,ADA,and AFP in the advanced patients were higher than those in the early and middle stage patients,while NAG,AFU,PAB,LAP,ASTM,GLDH,ADA,and AFP levels in the middle stage patients were higher than those in the early stage patients,the differences were statistically significant (P<0.05).Conclusion The implementation of biochemical test items for diagnosis of patients with liver cirrhosis in the clinic can provide effective reference value for later clinical treatment and promote a significant increase in clinical accuracy.
Key words font-size: 16px    Liver cirrhosis;Biochemical test items;Diagnostic value')" href="#">text-align: justify;">Liver cirrhosis;Biochemical test items;Diagnostic value
    
PACS:     
基金资助: 
作者简介: 纪金玲(1972-),女,汉族,辽宁辽阳人,本科,副主任技师,研究方向:生化检验诊断及质量管理
引用本文:   
纪金玲 程晓彤 王 茜 朱天星 杨娇娜.  生化检验项目在肝硬化疾病患者中的变化及意义[J]. 中国当代医药, 2020, 27(33): 164-166.
JI Jin-ling CHENG Xiao-tong WANG Qian ZHU Tian-xing YANG Jiao-na.  Changes and significance of biochemical test items in patients with liver cirrhosis. 中国当代医药, 2020, 27(33): 164-166.
链接本文:  
https://www.dangdaiyiyao.com/CN/     或     https://www.dangdaiyiyao.com/CN/Y2020/V27/I33/164
中华人民共和国互联网药品信息服务资格证书(京)-非经营性-2016-0092
京ICP备11001767号-6  京公网安备 11010502046607号  互联网药品信息服务资格证  期刊出版许可证  广告经营许可证
信息产业部备案管理系统网址 http://beian.miit.gov.cn/state/outPortal/loginPortal.action
投稿热线:010-59626690 总机:010-59626692/18/19/20   传真:010-59626204   投稿信箱:ddyy@vip.163.com
地址:北京市朝阳区东四环中路78号楼(大成国际中心B1座)8B02室   邮编:100124
技术支持:北京玛格泰克科技发展有限公司
Copyright 2000-2014 版权所有 《中国当代医药》杂志社 未经授权请勿转载